M
Manav Korpal
Researcher at Novartis
Publications - 40
Citations - 4263
Manav Korpal is an academic researcher from Novartis. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 16, co-authored 33 publications receiving 3889 citations. Previous affiliations of Manav Korpal include Brigham and Women's Hospital & Harvard University.
Papers
More filters
Journal ArticleDOI
The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2.
TL;DR: Loss of expression of the miR-200 family members may play a critical role in the repression of E-cadherin by ZEB1 and ZEB2 during EMT, thereby enhancing migration and invasion during cancer progression.
Journal ArticleDOI
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization
Manav Korpal,Brian Ell,Francesca M. Buffa,Toni Ibrahim,Mario Andres Blanco,Toni Celià-Terrassa,Laura Mercatali,Zia Khan,Hani Goodarzi,Yuling Hua,Yong Wei,Guohong Hu,Benjamin A. Garcia,Jiannis Ragoussis,Dino Amadori,Adrian L. Harris,Yibin Kang +16 more
TL;DR: A pleiotropic role of miR-200s is suggested in promoting metastatic colonization by influencing E-cadherin–dependent epithelial traits and Sec23a-mediated tumor cell secretome.
Journal ArticleDOI
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal,Joshua M. Korn,Xueliang Gao,Daniel P. Rakiec,David A. Ruddy,Shivang Doshi,Jing Yuan,Steve Kovats,Sunkyu Kim,Vesselina G. Cooke,John Monahan,Frank Stegmeier,Thomas M. Roberts,William R. Sellers,Wenlai Zhou,Ping Zhu +15 more
TL;DR: It is suggested that emergence of F876L may serve as a novel biomarker for prediction of drug sensitivity, predict a "withdrawal" response to MDV3100, and be suitably targeted with other antiandrogens or CDK4/6 inhibitors.
Journal ArticleDOI
The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis.
Manav Korpal,Yibin Kang +1 more
TL;DR: The miR-200 family has been shown to inhibit the initiating step of metastasis, epithelial-mesenchymal transition (EMT), by maintaining the epithelial phenotype through direct targeting of transcriptional repressors of E-cadherin, ZEB1 and ZEB2.
Journal ArticleDOI
Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis
TL;DR: This in vivo system for real-time manipulation and detection of TGF-β signaling provides a proof of principle for using similar strategies to analyze the in vivo dynamics of other metastasis-associated signaling pathways and will expedite the development and characterization of therapeutic agents.